Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA.

J Am Soc Nephrol. 2008 Feb;19(2):329-38. doi: 10.1681/ASN.2007040510. Epub 2008 Jan 23.

2.

Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.

Zhou G, Cheung AK, Liu X, Huang Y.

Clin Sci (Lond). 2014 May;126(10):707-20. doi: 10.1042/CS20130223.

PMID:
24195695
3.

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.

Huang Y, Border WA, Lawrence DA, Noble NA.

Kidney Int. 2006 Aug;70(3):515-22. Epub 2006 Jun 21.

4.

A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.

Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y.

Exp Physiol. 2014 May 1;99(5):802-15. doi: 10.1113/expphysiol.2013.077610. Epub 2014 Jan 17.

5.

An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.

Gu C, Zhang J, Noble NA, Peng XR, Huang Y.

Am J Physiol Renal Physiol. 2016 Nov 1;311(5):F852-F863. doi: 10.1152/ajprenal.00564.2015. Epub 2016 Aug 10.

6.
7.

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA.

J Clin Invest. 2003 Aug;112(3):379-88.

8.

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015-20.

9.

Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.

Seo JY, Park J, Yu MR, Kim YS, Ha H, Lee HB.

Am J Nephrol. 2009;30(6):481-90. doi: 10.1159/000242477. Epub 2009 Sep 25.

PMID:
19786738
10.

Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.

Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L.

Kidney Int. 2005 Dec;68(6):2651-66.

11.

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

Rossini M, Naito T, Yang H, Freeman M, Donnert E, Ma LJ, Dunn SR, Sharma K, Fogo AB.

Nephrol Dial Transplant. 2010 Jun;25(6):1803-10. doi: 10.1093/ndt/gfp724. Epub 2010 Jan 7.

12.

t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.

Haraguchi M, Border WA, Huang Y, Noble NA.

Kidney Int. 2001 Jun;59(6):2146-55.

13.

Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.

Jeong BY, Uddin MJ, Park JH, Lee JH, Lee HB, Miyata T, Ha H.

PLoS One. 2016 Jun 3;11(6):e0157012. doi: 10.1371/journal.pone.0157012. eCollection 2016.

14.

Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse.

Cohen MP, Masson N, Hud E, Ziyadeh F, Han DC, Clements RS.

Exp Nephrol. 2000 May-Jun;8(3):135-43.

PMID:
10810230
15.

Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.

Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN.

J Clin Invest. 1995 May;95(5):2338-45.

16.

Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.

Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H.

PLoS One. 2014 Jun 24;9(6):e100777. doi: 10.1371/journal.pone.0100777. eCollection 2014.

17.

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

Tang L, Wu Y, Tian M, Sjöström CD, Johansson U, Peng XR, Smith DM, Huang Y.

Am J Physiol Endocrinol Metab. 2017 Nov 1;313(5):E563-E576. doi: 10.1152/ajpendo.00086.2017. Epub 2017 Aug 15.

18.

Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.

Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.

Nephrol Dial Transplant. 2009 Jan;24(1):73-84. doi: 10.1093/ndt/gfn448. Epub 2008 Aug 5.

PMID:
18682491
19.

SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.

Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M.

Am J Physiol Renal Physiol. 2006 Apr;290(4):F813-20. Epub 2005 Nov 8.

20.

Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes.

Lin Y, Sun Z.

J Endocrinol. 2011 May;209(2):185-91. doi: 10.1530/JOE-10-0340. Epub 2011 Feb 9.

PMID:
21307121

Supplemental Content

Support Center